Fractyl Health (GUTS) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
24 Apr, 2026Executive summary
Annual meeting scheduled for June 10, 2026, with virtual participation available to shareholders.
Shareholders are encouraged to review proxy materials and vote by June 9, 2026.
Voting matters and shareholder proposals
Election of three directors: Marc Elia, Clive Meanwell, and Ian Sheffield, with board recommending a vote for each.
Ratification of Ernst & Young LLP as independent registered public accounting firm for the year ending December 31, 2026.
Provision for other business to be addressed as may properly come before the meeting.
Board of directors and corporate governance
Board slate includes Marc Elia, Clive Meanwell, and Ian Sheffield as nominees for election.
Partial view of Summaries dataset, powered by Quartr API
Latest events from Fractyl Health
- Revita enabled up to 84% weight loss retention at one year post-GLP-1, with strong safety data.GUTS
Study result17 Jul 2026 - Innovative device and gene therapy programs target durable weight maintenance in obesity and diabetes.GUTS
Chardan's 8th Annual Genetic Medicines Conference8 Jul 2026 - Director elections and auditor ratification approved; no questions raised by stockholders.GUTS
AGM 202610 Jun 2026 - Q1 2026 net income turned positive on non-cash gains; cash runway into early 2027.GUTS
Q1 202619 May 2026 - Revita targets durable weight maintenance post-GLP-1, with pivotal data and filing expected in 2024.GUTS
Bank of America Global Healthcare Conference 202614 May 2026 - Stockholders will vote on director elections and auditor ratification, with a focus on governance and transparency.GUTS
Proxy filing25 Apr 2026 - Pivotal study fully enrolled, strong results, cash runway into 2027, no capital raise planned.GUTS
Q4 202524 Mar 2026 - Revita sustains weight loss and safety post-GLP-1, with pivotal data and FDA milestones ahead.GUTS
Study result3 Feb 2026 - Q2 net loss narrowed, cash rose to $102.4M, and Revita gained FDA Breakthrough status.GUTS
Q2 20241 Feb 2026